As a bispecific antibody with a relative molecular mass of 55 kDa (3), blinatumomab mainly kills tumor cells by targeting CD19-positive tumor cells and CD3-positive T cells, forming tight target cell-cell contacts (4), and releasing interleukins, interferons, tumor necrosis factor, perforin, and granzymes (5, 6). The gene discussed is TNF; the disease is neoplasm.